Cellular Technologies

Enhanced, streamlined approaches to facilitate CRISPR/Cas9-mediated gene activation.

Monday, February 5
12:00 PM - 12:30 PM
Location: 6D

CRISPR/Cas9 is conventionally used as a loss-of-function tool within the context of cell-based genetic screens. However, modification of Cas9 can convert it from a targeted DNA damaging enzyme into a transcriptional activator, thus enabling its use for gain-of-function studies. We have developed a suite of vectors that streamline the process of generating a stable, effective CRISPR/Cas9 activator cell line. Here, we will describe the comparative performance of different Cas9-activator combinations expressed from these vectors, and we will discuss best practices and potential pitfalls when engineering cells to be competent for CRISPR-mediated gene activation.

Benjamin Haley

Senior Scientist
Genentech, Inc

During his graduate studies at UMass Medical School, Ben unraveled several biochemical mechanisms that characterize the RNAi pathway. After receiving his PhD, he went to Michael Levine’s lab at UC Berkeley as an American Cancer Society Postdoctoral Fellow. There, he developed an enhanced Drosophila RNAi system for in vivo applications, further refined the in vivo specificity of RNAi, and identified novel aspects of small RNA biogenesis and mRNA structure/expression using a host of model organisms. Following his postdoc, Ben joined Genentech, Inc. where he currently serves as a point person for applied functional genetics. His lab is focused on developing technologies to better model human disease and therapeutic intervention using cell-based experiments.

Presentation(s):

Send Email for Benjamin Haley


Assets

Enhanced, streamlined approaches to facilitate CRISPR/Cas9-mediated gene activation.



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Enhanced, streamlined approaches to facilitate CRISPR/Cas9-mediated gene activation.